World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
99
Citations
53782
World Ranking
737
National Ranking
418

Medicine

D-Index
99
Citations
53700
World Ranking
8427
National Ranking
4357

Overview

Paul F. Robbins is affiliated with the National Institutes of Health in the United States. Their research primarily spans the fields of medicine and immunology and microbiology, with a focus on oncology, immunology, molecular biology, cancer research, and genetics.

Their work covers key topics including CAR-T cell therapy research, immunotherapy and immune responses, cancer immunotherapy and biomarkers, immune cell function and interaction, cancer genomics and diagnostics, T-cell and B-cell immunology, and vaccines and immunoinformatics approaches.

Robbins has published extensively, with recent papers including:

  • "Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer," 2020, Science
  • "Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers," 2022, Science
  • "mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer," 2020, Journal of Clinical Investigation
  • "A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers," 2022, Cancer Cell
  • "Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors," 2022, Cancer Immunology Research

Frequent co-authors in Robbins' research include:

  • Steven A. Rosenberg
  • Frank J. Lowery
  • Jared J. Gartner
  • Maria R. Parkhurst
  • Todd D. Prickett

The most common publication venues for Robbins' work are:

  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Clinical Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Cancer Cell

Best Publications

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

    Yutaka Kawakami;Siona Eliyahu;Cynthia H. Delgado;Paul F. Robbins

  • T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

    Eric Tran;Paul F. Robbins;Yong Chen Lu;Todd D. Prickett

  • A listing of human tumor antigens recognized by T cells.

    Nicolina Renkvist;Chiara Castelli;Paul F. Robbins;Giorgio Parmiani

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

    Paul F. Robbins;Yong Chen Lu;Mona El-Gamil;Yong F. Li

  • PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

    Alena Gros;Paul F. Robbins;Xin Yao;Yong F. Li

  • Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

    Y Kawakami;S Eliyahu;C H Delgado;P F Robbins

  • Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

    Yutaka Kawakami;Siona Eliyahu;Kazuyasu Sakaguchi;Paul F. Robbins

  • Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

    Alena Gros;Maria R Parkhurst;Eric Tran;Anna Pasetto

  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  • Immunogenicity of somatic mutations in human gastrointestinal cancers

    Eric Tran;Mojgan Ahmadzadeh;Yong Chen Lu;Alena Gros

  • Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

    Nikolaos Zacharakis;Harshini Chinnasamy;Mary Black;Hui Xu

  • Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

    Maria R. Parkhurst;Michael L. Salgaller;Scott Southwood;Paul F. Robbins

  • Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

    Y. Kawakami;S. Eliyahu;C. Jennings;K. Sakaguchi

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Maria R. Parkhurst
Maria R. Parkhurst National Institutes of Health
Yutaka Kawakami
Yutaka Kawakami International University Of Health And Welfare Atami Hospital
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
John R. Wunderlich
John R. Wunderlich National Institutes of Health
Rongfu Wang
Rongfu Wang University of Southern California
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, expanding your qualifications through online degrees can open up diverse healthcare career paths. Nursing professionals, for example, often pursue advanced degrees to specialize and increase their earning potential. The highest paid DNP specialties provide insight into which fields offer the best financial rewards, helping guide your specialization choices.

Transitioning from a Family Nurse Practitioner (FNP) to an Acute Care Nurse Practitioner (ACNP) is a common route for those interested in critical care settings. Learning how to make this switch effectively can enhance job opportunities and clinical skills. Resources on how to fnp to acnp transitions outline the necessary certifications and training involved.

Accelerated degree programs are gaining popularity among busy professionals looking to fast-track their careers. Enrolling in an accelerated NP program offers a streamlined curriculum to quickly gain nurse practitioner credentials and move into advanced clinical roles.

Furthermore, individuals without a nursing background who are drawn to healthcare can explore quality online nursing programs for non nurses. These options provide foundational knowledge and skills, making it feasible to transition into nursing careers that complement immunology expertise.

Best Scientists Citing Paul F. Robbins

Trending Scientists